Second-line Chemotherapy with Paclitaxel and Carboplatin for Patients with Recurrent Ovarian Carcinoma / 대한산부인과학회잡지
Korean Journal of Obstetrics and Gynecology
;
: 1915-1920, 2004.
Artigo
em Coreano
| WPRIM
| ID: wpr-47573
ABSTRACT
OBJECTIVE:
This study is to investigate the efficacy and toxicity of paclitaxel plus carboplatin used as a salvage therapy.METHODS:
Between June 2000 and November 2003, 10 patients aged 43-74 (median 55.0) with recurrent ovarian carcinoma were given combination chemotherapy including paclitaxel and carboplatin. The subjects received initial chemotherapy with paclitaxel plus cisplatin/carboplatin. On recurrence, paclitaxel was administered intravenously at a dose of 175 mg/m2 with carboplatin by AUC 5 every 3 weeks. The median treatment cycle was 10 cycles (range, 1 to 15 cycles). Recurrence of ovarian carcinoma was determined by elevation of serum CA-125, or radiologic imaging. Responses and toxicities were evaluated according to Gynecologic Oncology Group criteria and Common Terminology Criteria for Adverse Events from NCI (National Cancer Institute).RESULTS:
The overall clinical response rate was 60.0% (6/10). Better response was observed in patients who were sensitive with initial chemotherapy. Anemia was the most frequent complication.CONCLUSION:
Paclitaxel and carboplatin has been shown to be a feasible agent in patients with recurrent ovarian cancer.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Ovarianas
/
Recidiva
/
Carboplatina
/
Terapia de Salvação
/
Paclitaxel
/
Área Sob a Curva
/
Tratamento Farmacológico
/
Quimioterapia Combinada
/
Anemia
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Obstetrics and Gynecology
Ano de publicação:
2004
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS